What does the drug do?

ILB is a pleiotropic molecule which means it is believed to have multiple effects in the body. Its active component, a patented form of dextran sulphate, targets multiple pathways that are involved in the loss of function and death of neurons, which is characteristic of MND and other neurological diseases. It is administered via a subcutaneous (under-the-skin) injection.

Phase 2

The Phase 2 open label trial aimed at investigating the safety and tolerability of ILB enrolled 11 participants. The participants took 2 mg/kg of ILB, by subcutaneous (under the skin) injection once a week for 48 weeks. You can read more about the trial here.

The trial is fully recruited in the UK and Republic of Ireland.

Latest News

May 2022 - TikoMed announce results from a Swedish trial of ILB that show some improvement in ALSFRS-R scores and decreased levels of biomarkers associated with muscle wasting. Results from the UK trial are expected in 2022. Find out more here.

Aug 2020 - ILB was named an orphan drug in Europe

Last updated: 01/08/2022

For further information and support contact our MND Connect helpline

mndconnect 0808 802 6262